AR112192A1 - Compuestos de azaindol como inhibidores de histona metiltransferasa - Google Patents

Compuestos de azaindol como inhibidores de histona metiltransferasa

Info

Publication number
AR112192A1
AR112192A1 ARP180101557A AR112192A1 AR 112192 A1 AR112192 A1 AR 112192A1 AR P180101557 A ARP180101557 A AR P180101557A AR 112192 A1 AR112192 A1 AR 112192A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
haloalkoxy
haloalkyl
halo
Prior art date
Application number
Other languages
English (en)
Spanish (es)
Original Assignee
Global Blood Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Global Blood Therapeutics Inc filed Critical Global Blood Therapeutics Inc
Publication of AR112192A1 publication Critical patent/AR112192A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ARP180101557 2017-06-09 2018-06-08 Compuestos de azaindol como inhibidores de histona metiltransferasa AR112192A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762517410P 2017-06-09 2017-06-09

Publications (1)

Publication Number Publication Date
AR112192A1 true AR112192A1 (es) 2019-10-02

Family

ID=62779058

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101557 AR112192A1 (es) 2017-06-09 2018-06-08 Compuestos de azaindol como inhibidores de histona metiltransferasa

Country Status (11)

Country Link
US (2) US11111243B2 (enExample)
EP (1) EP3634962B1 (enExample)
JP (1) JP7225125B2 (enExample)
CN (1) CN110997671A (enExample)
AR (1) AR112192A1 (enExample)
BR (1) BR112019025770A2 (enExample)
ES (1) ES2949402T3 (enExample)
IL (1) IL271066A (enExample)
MX (1) MX2019014759A (enExample)
TW (1) TW201920165A (enExample)
WO (1) WO2018226998A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.
JP7749679B2 (ja) * 2021-02-05 2025-10-06 シンノハブ ファーマシューティカル カンパニー，リミティド プラスミン阻害剤、その製造方法およびその適用
CN114394971B (zh) * 2022-01-24 2023-01-31 云南大学 一种吲哚咔唑类化合物的制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2402549A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines
US20080207632A1 (en) 2006-10-31 2008-08-28 Supergen, Inc. Protein kinase inhibitors
RU2532135C2 (ru) 2007-02-22 2014-10-27 Зингента Партисипейшнс Аг Производные иминопиридина и их применение в качестве микробиоцидов
AU2008343932B2 (en) * 2007-12-19 2013-08-15 Amgen Inc. Fused pyridine, pyrimidine and triazine compounds as cell cycle inhibitors
US8932557B2 (en) * 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
PL2364983T3 (pl) 2008-11-11 2014-04-30 Jeil Pharmaceutical Co Ltd Nowa pochodna tricykliczna lub jej farmaceutycznie dopuszczalne sole, sposób jej wytwarzania, oraz zawierająca ją kompozycja farmaceutyczna
PL2485731T4 (pl) * 2009-10-06 2017-07-31 Millennium Pharmaceuticals, Inc. Związki heterocykliczne użyteczne jako inhibitory PDK1
WO2011133795A2 (en) * 2010-04-22 2011-10-27 The Brigham And Women's Hospital, Inc. Beta-carbolines as inhibitors of haspin and dyrk kinases
US9168247B2 (en) * 2010-06-25 2015-10-27 Facultes Universitaires Notre Dame De La Paix Beta carboline derivatives useful in the treatment of proliferative disorders
TW201236880A (en) 2011-03-11 2012-09-16 Primax Electronics Ltd Sheet feeding apparatus
KR101606250B1 (ko) 2011-03-23 2016-03-24 암젠 인크 Cdk 4/6 및 flt3의 융합된 트리사이클릭 이중 저해제
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
US9284272B2 (en) 2014-03-28 2016-03-15 Abbvie Inc. Inhibitors of histone methyltransferase G9a
DK3154957T3 (da) 2014-06-16 2020-02-17 Fundacion Para La Investig Medica Aplicada Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser
US10407423B2 (en) 2015-11-16 2019-09-10 Fundación Para La Investigación Médica Aplicada Compounds as inhibitors of DNA methyltransferases
MX2019014759A (es) * 2017-06-09 2020-02-12 Global Blood Therapeutics Inc Compuestos de azaindol como inhibidores de metiltransferasa de histona.

Also Published As

Publication number Publication date
JP2020523315A (ja) 2020-08-06
JP7225125B2 (ja) 2023-02-20
IL271066A (en) 2020-01-30
CN110997671A (zh) 2020-04-10
EP3634962A1 (en) 2020-04-15
EP3634962B1 (en) 2023-05-24
TW201920165A (zh) 2019-06-01
WO2018226998A1 (en) 2018-12-13
US20180354947A1 (en) 2018-12-13
ES2949402T3 (es) 2023-09-28
US20210371417A1 (en) 2021-12-02
MX2019014759A (es) 2020-02-12
US11111243B2 (en) 2021-09-07
BR112019025770A2 (pt) 2020-06-23

Similar Documents

Publication Publication Date Title
AR088423A1 (es) Ligadores p1 ciclicos como inhibidores del factor xia
AR100807A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR113965A1 (es) Triazol azoles ciclohexil ácidos como antagonistas de lpa
AR093579A1 (es) Inhibidores de bmi-1 de pirimidina inversa sustituida
AR098666A1 (es) Compuestos de biarilacetamida y sus métodos de uso
AR093580A1 (es) Inhibidores bmi-1 de pirimidina sustituidos
AR113929A1 (es) Compuestos heterocíclicos
EA202192019A1 (ru) Производные 3-(1-оксо-5-(пиперидин-4-ил)изоиндолин-2-ил)пиперидин-2,6-диона и пути их применения
AR100975A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR101189A1 (es) Heterociclos nitrogenados antiproliferativos y sus métodos de uso
AR108130A1 (es) Derivados de pirazolopirimidina
AR091981A1 (es) Dihidropiridona p1 como inhibidores del factor xia
AR110405A1 (es) Compuestos
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR110753A1 (es) Inhibidores selectivos de jak1
AR108388A2 (es) Compuestos de oxazol sustituidos con indazol como inhibidores de pi3-quinasas
AR103990A1 (es) Ureas cíclicas como inhibidoras de rock
AR100886A1 (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
AR088029A1 (es) Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR107321A1 (es) Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
AR095351A1 (es) Inhibidores de histona desacetilasa (hdac)
AR088630A1 (es) Inhibidores del virus de la hepatitis c
AR100806A1 (es) Inhibidores de fosfatidilinositol 3-quinasa

Legal Events

Date Code Title Description
FB Suspension of granting procedure